1. Baldanti, F., Lurain, N., & Gerna, G. (2004). Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Human Immunology, 65(5), 403–409.
2. Belaid, A., Aouni, M., Khelifa, R., Trabelsi, A., Jemmali, M., & Hani, K. (2002). In vitro antiviral activity of dermaseptins against herpes simplex virus type 1. Journal of Medical Virology, 66(2), 229–234.
3. Bocket, L., Cheret, A., Deuffic-Burban, S., Choisy, P., Gerard, Y., de la Tribonnière, X., Viget, N., Ajana, F., Goffard, A., Barin, F., & Mouton, Y. (2005). Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antiviral Therapy, 10(2), 247–254.
4. Borroto-Esoda, K., Vela, J. E., Myrick, F., Ray, A. S., & Miller, M. D. (2006). In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antiviral Therapy, 11(3), 377.
5. Brisson, M., Edmunds, W. J., & Gay, N. J. (2003). Varicella vaccination: Impact of vaccine efficacy on the epidemiology of VZV. Journal of Medical Virology, 70(S1), S31–S37.